Scandinavian ChemoTech Q1: Clinical performance in the right direction - Redeye

Redeye leaves its comments on Scandinavian ChemoTech following the company’s Q1 2023 report. The report contained no significant surprises, but the company reported slightly lower OPEX than expected. We largely maintain our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/910777/scandinavian-chemotech-q1-clinical-performance-in-the-right-direction?utm_source=finwire&utm_medium=RSS